Related references
Note: Only part of the references are listed.Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
Jack Patrick Gleeson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance
Migyeong Jo et al.
MABS (2018)
Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer
Takahiro Nakajima et al.
ONCOLOGY LETTERS (2018)
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Hamid Maadi et al.
BMC CANCER (2018)
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
Cecile A. W. Geuijen et al.
CANCER CELL (2018)
Treatment of advanced HER2-positive breast cancer: 2018 and beyond
Noam Ponde et al.
CANCER TREATMENT REVIEWS (2018)
Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors
Diego Sanchez-Martinez et al.
THERANOSTICS (2018)
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Maria F. Mercogliano et al.
CLINICAL CANCER RESEARCH (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Advances in the management of HER2-positive early breast cancer
Jose Baselga et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
Feng Xu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines
Denis M. Collins et al.
CELLULAR IMMUNOLOGY (2017)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Y. J. Bang et al.
ANNALS OF ONCOLOGY (2017)
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
Martina Di Modica et al.
ONCOTARGET (2016)
Pertuzumab and trastuzumab: the rationale way to synergy
Sandrine Richard et al.
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS (2016)
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Jennifer L. Hsu et al.
CANCER AND METASTASIS REVIEWS (2016)
Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment
Guowei Gu et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes
Nishant Mohan et al.
MOLECULAR CANCER THERAPEUTICS (2016)
X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity
M. K. Evans et al.
CELL DEATH & DISEASE (2016)
A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells
Hilal S. Khalil et al.
ONCOTARGET (2016)
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
Caroline Jochems et al.
ONCOTARGET (2016)
A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor
Erika Kovacs et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 84 (2015)
Targeting HER2 for the Treatment of Breast Cancer
Mothaffar F. Rimawi et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
Sharon T. Wilks
BREAST (2015)
Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+breast cancer
Callie R. Merry et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
Otilia Menyhart et al.
CURRENT CANCER DRUG TARGETS (2015)
Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
Yun Shi et al.
JOURNAL OF IMMUNOLOGY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells
Riki Okita et al.
ONCOLOGY REPORTS (2015)
Molecular architecture of the ErbB2 extracellular domain homodimer
Shi Hu et al.
ONCOTARGET (2015)
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
N. Elster et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2
Wai-Heng Lua et al.
NPJ BREAST CANCER (2015)
Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity
Minh Ngoc Duong et al.
BREAST CANCER RESEARCH (2015)
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition
Milos Dokmanovic et al.
CANCER BIOLOGY & THERAPY (2014)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Neil A. O'Brien et al.
CLINICAL CANCER RESEARCH (2014)
Emerging EGFR antagonists for breast cancer
Ana Lluch et al.
EXPERT OPINION ON EMERGING DRUGS (2014)
P95 HER2 fragments and breast cancer outcome
Deniz Tural et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic
Alessandra Fabi et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Epidermal Growth Factor Receptor Inhibitors: Coming of Age
Amit Mahipal et al.
CANCER CONTROL (2014)
Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy
Alexey Goltsov et al.
CELLS (2014)
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+breast cancer cells
Brent N. Rexer et al.
BREAST CANCER RESEARCH (2014)
Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity
Sang Taek Jung et al.
ACS CHEMICAL BIOLOGY (2013)
Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer
Leticia De Mattos-Arruda et al.
ADVANCES IN THERAPY (2013)
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
Allan Lipton et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Oncogenic ERBB3 Mutations in Human Cancers
Bijay S. Jaiswal et al.
CANCER CELL (2013)
Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3
Malgorzata Magdalena Sak et al.
CARCINOGENESIS (2013)
Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845
Ken-ichi Sato
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
Branka Petricevic et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes
Denise A. Yardley
INTERNATIONAL JOURNAL OF BREAST CANCER (2013)
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
J. D. Jensen et al.
ANNALS OF ONCOLOGY (2012)
Role of epidermal growth factor receptor in breast cancer
Hiroko Masuda et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
A. Gallardo et al.
BRITISH JOURNAL OF CANCER (2012)
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
A. H. Sims et al.
BRITISH JOURNAL OF CANCER (2012)
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Celina Garcia-Garcia et al.
CLINICAL CANCER RESEARCH (2012)
Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
Naoki Niikura et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells
Timothy Kute et al.
ONCOIMMUNOLOGY (2012)
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
K. Tamura et al.
ANNALS OF ONCOLOGY (2011)
Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells
Jayashree P. Joshi et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
E. Razis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Ritwik Ghosh et al.
CANCER RESEARCH (2011)
Function of ERBB4 is determined by alternative splicing
Ville Veikkolainen et al.
CELL CYCLE (2011)
Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
Yoriko Yamashita-Kashima et al.
CLINICAL CANCER RESEARCH (2011)
Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies
Dana Faratian et al.
CLINICAL CANCER RESEARCH (2011)
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Chang Gong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Gabriel L. Fiszman et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2011)
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
Gloria Fuentes et al.
BREAST CANCER RESEARCH (2011)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Y. Kataoka et al.
ANNALS OF ONCOLOGY (2010)
Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
Guanglei Zhuang et al.
CANCER RESEARCH (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway
Rita Nahta et al.
CLINICAL BREAST CANCER (2010)
Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
Jeff Sperinde et al.
CLINICAL CANCER RESEARCH (2010)
Potential of ErbB4 antibodies for cancer therapy
Maija Hollmen et al.
FUTURE ONCOLOGY (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Immunohistochemical Expression of HER1, HER3, and HER4 in HER2-Positive Breast Cancer Patients Treated With Trastuzumab-Containing Neoadjuvant Chemotherapy
Kan Yonemori et al.
JOURNAL OF SURGICAL ONCOLOGY (2010)
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Fumin Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeting erbB receptors
Zheng Cai et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2010)
HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Merel Gijsen et al.
PLOS BIOLOGY (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment
Jaume Capdevila et al.
CANCER TREATMENT REVIEWS (2009)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2009)
ErbB receptors and signaling pathways in cancer
Nancy E. Hynes et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
ADAM17 as a Therapeutic Target in Multiple Diseases
Joaquin Arribas et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Ligand-induced ErbB receptor dimerization
Mark A. Lemmon
EXPERIMENTAL CELL RESEARCH (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
Kim Pedersen et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Functional selectivity of EGF family peptide growth factors: Implications for cancer
Kristy J. Wilson et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Structure-based view of epidermal growth factor receptor regulation
Kathryn M. Ferguson
ANNUAL REVIEW OF BIOPHYSICS (2008)
System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties
Alexis Kaushansky et al.
CHEMISTRY & BIOLOGY (2008)
EGFR family: Structure physiology signalling and therapeutic targets
Antony W. Burgess
GROWTH FACTORS (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer
Frank E. Jones
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway
Kazuko Sakai et al.
CANCER SCIENCE (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy
X-F Wen et al.
ONCOGENE (2006)
Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain
S. Pablo Sardi et al.
CELL (2006)
Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner
Jennifer E. Skeen et al.
CANCER CELL (2006)
HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer -: A study of two hundred cases
A. Saez et al.
BREAST (2006)
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
Judit Anido et al.
EMBO JOURNAL (2006)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers
WL Xia et al.
CANCER RESEARCH (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
N Takai et al.
CANCER (2005)
Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2
KE Longva et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The ErbB receptors and their ligands in cancer: An overview
N Normanno et al.
CURRENT DRUG TARGETS (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
TGFα expression impairs trastuzumab-induced HER2 downregulation
G Valabrega et al.
ONCOGENE (2005)
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity
BS Kochupurakkal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Phosphotyrosine interactome of the ErbB-receptor kinase family
Waltraud X. Schulze et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Neuroglycan C, a novel member of the neuregulin family
Y Kinugasa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
CD Austin et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Purification of Her-2 extracellular domain and identification of its cleavage site
CX Yuan et al.
PROTEIN EXPRESSION AND PURIFICATION (2003)
ErbB-4: mechanism of action and biology
G Carpenter
EXPERIMENTAL CELL RESEARCH (2003)
Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma
YT Kim et al.
GYNECOLOGIC ONCOLOGY (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Tumor biology - Herceptin acts as an anti-angiogenic cocktail
Y Izumi et al.
NATURE (2002)
Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor
NJ Hellyer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation
J Okano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
